Single answer
Is Achilles Therapeutics plc (ACHL) a buy or sell?
4starter turns market data into one clear verdict you can act on.
Create a free account to save tickers and track your signals.
Log in to turn on watchlist alerts.
Decision snapshot
Everything you need to act fast, in one glance.
What is the conclusion?
Right now our advanced algorithms say:
Do analysts agree?
We compare consensus targets with today's price.
Consensus target for Achilles Therapeutics plc is $2.00, which is $0.520 (35.14%) above the current price today's price.
Low target: $2.00 | High target: $2.00
Company snapshot
A quick overview of the business and its public profile.
Achilles Therapeutics Plc a clinical stage immunooncology biopharmaceutical company develops precision T cell therapies to treat various solid tumors The companys lead product candidates include CHIRON which is in Phase IIIa clinical trial for use in the treatment of advanced nonsmall cell lung cancer and THETIS a product candidate in Phase IIIa clinical trial for use in the treatment of metastatic or recurrent melanoma It is also developing products for use in the treatment of head and neck squamous cell carcinoma renal cell carcinoma triple negative breast cancer and bladder cancer The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021 The company was founded in 2016 and is headquartered in London the United Kingdom
Website: httpswwwachillestxcom
Rates and inflation backdrop
US inflation for January 2026 was 0.17%. Over the last 12 months, inflation is 2.83%. The 10-year yield is 4.04 and is down -0.110 over the last 30 days.
Inflation sensitivity
Debt ratio: 0.03. Cash flow to debt ratio: -10.50. Net profit margin: 0.00%. Inflation risk score: medium (0.60/1).
Dividend history check
We cannot find any recorded dividends paid in our systems.
Trading liquidity
Yes, the average daily trading liquidity for Achilles Therapeutics plc is $1.1M. You should therefore be able to get in and out of your positions relatively fast.
10-year return check
We cannot find data for Achilles Therapeutics plc 10 years ago, but if you had invested on 2021-03-31 when the price was $16.55, you would have made a loss of $15.07 per share or 91.06%.
Why this answer
We combine price momentum, volatility, and trend signals to simplify the decision to one word.
Signal engine scans price, trend, and momentum indicators.
Targets and sentiment are checked against the live quote.
We keep the output simple: buy, sell, or hold.
Analyst consensus
How Wall Street targets compare to today's price.